Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517875 · ClinicalTrials.gov registry record · Phase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 14
- Study locations
NCT06517875: Recruiting Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, sponsored by GlaxoSmithKline.
NCT06517875 is a Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 56 participants, below the 119-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (53% lower). The trial reports 14 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06517875, a Phase 2 study of Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
Primary Outcome
TI response is defined as not requiring red blood cell (RBC) transfusion (except in the case of clinically overt bleeding) for any ≥12-week interval.
Conditions Studied
Interventions
- DRUG Luspatercept
- DRUG Momelotinib
Study Locations (14)
Other
- GSK Investigational Site - Angers
- GSK Investigational Site - Brest
- GSK Investigational Site - Lyon
- GSK Investigational Site - Nice
- GSK Investigational Site - Nîmes
- GSK Investigational Site - Paris
- GSK Investigational Site - Poitiers
- GSK Investigational Site - Florence
- GSK Investigational Site - Roma
- GSK Investigational Site - Málaga
- GSK Investigational Site - Valencia
Tennessee
- GSK Investigational Site - Nashville
Ontario
- GSK Investigational Site - Toronto
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2026-11-13 |
| Phase | Phase 2 |
What NCT06517875 shows while recruiting
NCT06517875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 119-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Luspatercept is the first listed.
NCT06517875 lists 14 locations in 4 states (Other, Tennessee, Ontario).
Frequently Asked Questions
What is clinical trial NCT06517875 about?
NCT06517875 is a clinical study titled "Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis". The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who ar...
What is the current status of trial NCT06517875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-02-28. Estimated completion is 2026-11-13.
What conditions does trial NCT06517875 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis.
What interventions are being tested in trial NCT06517875?
The interventions under investigation include: Luspatercept (DRUG), Momelotinib (DRUG).
Who is sponsoring clinical trial NCT06517875?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517875 being conducted?
This trial has 14 study locations across Tennessee, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06517875's enrollment target sits among peer trials
56 16th of 30 higher than 15 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI